“The benefits of hormone therapy outweigh the risks
for most healthy symptomatic women who are
aged younger than 60 years and within 10 years of…”.1

Umbrella
What may the Hormone Therapy and Aging Umbrella include?

Depending on the Source (DotS) this Umbrella may include:

  • Hormone Replacement Therapy (HRT) and Aging/Prevention/Protection
  • Hormone Therapy (HT) and Aging/Prevention/Protection
  • Menopausal Hormone Therapy (MHT) and Aging/Prevention/Protection

Benefits and Risks

What are the benefit and risks of hormone therapy (HT) associated with aging?

On page one in The North American Menopause Society Releases Its 2022 Hormone Therapy Position Statement published 07 July June 2022, the North American Menopause Society (NAMS) explain:

  • “The benefits of hormone therapy outweigh the risks for most healthy symptomatic women who are aged younger than 60 years and within 10 years of menopause onset”.2

Disease Prevention

Is HT recommended for disease prevention?

On page four in the Joint Position Statement By the British Menopause Society, Royal College of Obstetricians and Gynaecologists and Society for Endocrinology on Best Practice Recommendations for the Care of Women Experiencing the Menopause, first published online 10 June 2022, one of the recommendations is:

“HRT should not be recommended for the primary or secondary prevention of chronic disease in women experiencing the menopause in keeping with national and international guidelines”.3

2022 USPSTF Recommendations

What were the United States Preventative Services Task Force (USPSTF) recommendations about HT for the primary prevention of chronic conditions, published 01 November 2022?

Hormone Therapy and AgingIn Hormone Therapy In Postmenopausal Persons: Primary Prevention of Chronic Conditions – Recommendation Summary, the USPSTF recommend:

“Postmenopausal persons
The USPSTF recommends against the use of combined estrogen and progestin for the primary prevention of chronic conditions in postmenopausal persons”.4

Hormone Therapy and AgingIn Hormone Therapy In Postmenopausal Persons: Primary Prevention of Chronic Conditions – Recommendation Summary, the USPSTF recommended:

“Postmenopausal persons who have had a hysterectomy
The USPSTF recommends against the use of estrogen alone for the primary prevention of chronic conditions in postmenopausal persons who have had a hysterectomy”.5

Heart Disease

How may heart disease be prevented?

In Menopause FAQs: Your Health After Menopause – Q. Do I have to start worrying about heart disease? the NAMS elaborate on:

“A. You do. Although many women think of heart disease as a man’s disease, the number one killer of women in North America is cardiovascular disease, that is, diseases of the heart and circulatory system. After age 55, more than half of all the deaths in women are caused by cardiovascular disease. Risk for this disease increases after menopause. Be sure to talk to your healthcare team about what your risks are and how you can reduce them”.6

Osteoporosis

How may osteoporosis be prevented?

In Menopause FAQs: Your Health After Menopause – Q. What can I do to prevent osteoporosis? the NAMS elaborate on

“A. …Talk to your healthcare provider about your risk of osteoporosis and what you can do to help keep your bones strong, especially with good nutrition and exercise”.7

Stop or Not

If I am an older than 60 years, do I need to discontinue HT?

On page one in The North American Menopause Society Releases Its 2022 Hormone Therapy Position Statement the NAMS note:

Hormone Therapy and Aging

  • “Hormone therapy does not need to be routinely discontinued in women aged older than 60 or 65 years and can be considered for continuation beyond age 65 for persistent VMS, quality-of-life issues, or prevention of osteoporosis after appropriate evaluation and counseling of benefits and risks”.8

Health Care Provider

What if I would like to choose to use HT?

If you choose to use HT, it may be in your best interest to also choose to talk to your health care provider about this.

On page two in the Joint Position Statement By the British Menopause Society, Royal College of Obstetricians and Gynaecologists and Society for Endocrinology on Best Practice Recommendations for the Care of Women Experiencing the Menopause, first published online 10 June 2022, one of the recommendations is:

  • “The decision whether to take HRT, the dose and duration of its use should be made on an individualised basis after discussing the benefits and risks with each patient. This should be considered in the context of the overall benefits obtained from using HRT including symptom control and improving quality of life as well as considering the bone and cardiovascular benefits associated with HRT use. Discussions with women should also cover aspects such as when to consider stopping HRT and how this can be done (by gradually reducing the dose of HRT). No arbitrary limits should be set on age or duration of HRT intake”.9

Health Topics A-Z

Where may I find Health Topics related to Hormone Therapy and Aging?

In Health Topics A-Z you may find:

Links

Where may I find Links related to Hormone Therapy and Aging?

Your Country may have Links similar to:

Sources

Where may I find the Sources quoted?

You may find the Sources at:

Sources

  1. The North American Menopause Society Releases Its 2022 Hormone Therapy Position Statement. 07 July 2022:1. North American Menopause Society https://www.menopause.org/docs/default-source/press-release/ht-position-statement-release.pdf Accessed: 28 February 2023
  2. Hamoda, H., Mukherjee, A., Morris, E., Baldeweg, S. E., Jayasena, C. N., Briggs, P., Moger, S. Joint Position Statement By the British Menopause Society, Royal College of Obstetricians and Gynaecologists and Society for Endocrinology on Best Practice Recommendations for the Care of Women Experiencing the Menopause. First Published Online 10 June 2022:4. https://journals.sagepub.com/doi/full/10.1177/20533691221104879 Accessed: 28 February 2023
  3. The North American Menopause Society Releases Its 2022 Hormone Therapy Position Statement. 07 July 2022:1. North American Menopause Society https://www.menopause.org/docs/default-source/press-release/ht-position-statement-release.pdf Accessed: 28 February 2023
  4. Hormone Therapy In Postmenopausal Women: Primary Prevention of Chronic Conditions – Clinician Summary: To Whom Does This Recommendation Apply. 01 November 2022. U.S. Preventative Services Task Force https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/menopausal-hormone-therapy-preventive-medication Accessed: 28 February 2023
  5. Hormone Therapy In Postmenopausal Women: Primary Prevention of Chronic Conditions – Clinician Summary: To Whom Does This Recommendation Apply. 01 November 2022. U.S. Preventative Services Task Force https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/menopausal-hormone-therapy-preventive-medication Accessed: 28 February 2023
  6. Menopause FAQs: Your Health After Menopause – Q. Do I have to start worrying about heart disease? North American Menopause Society https://www.menopause.org/for-women/menopause-faqs-your-health-after-menopause Accessed: 28 February 2023
  7. Menopause FAQs: Your Health After Menopause – Q. What can I do to prevent osteoporosis? North American Menopause Society https://www.menopause.org/for-women/menopause-faqs-your-health-after-menopause Accessed: 28 February 2023
  8. The North American Menopause Society Releases Its 2022 Hormone Therapy Position Statement. 07 July 2022:1. North American Menopause Society https://www.menopause.org/docs/default-source/press-release/ht-position-statement-release.pdf Accessed: 28 February 2023
  9. Hamoda, H., Mukherjee, A., Morris, E., Baldeweg, S. E., Jayasena, C. N., Briggs, P., Moger, S. Optimising the Menopause Transition: Joint Position Statement By the British Menopause Society, Royal College of Obstetricians and Gynaecologists and Society for Endocrinology on Best Practice Recommendations for the Care of Women Experiencing the Menopause. First Published Online 10 June 2022:2 https://journals.sagepub.com/doi/10.1177/20533691221104882 Accessed: 28 February 2023
Topic Last Updated: 28 February 2023  – Topic Last Reviewed: 28 February 2023

Print Friendly, PDF & Email